UNSPSC 51453005: Piperazine citrate

This classification denotes an antihelminthic agent with the molecular formula 2C6H8O7.3C4H10N2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63KP7FXF2I, chemically known as 1,4-piperazine but more generally known as piperazine citrate, which bears US NIH Compound Identifier 4837. European Medicines Agency schedules Piperazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14884MIG.

Most nations, for tariff and trade purposes, schedule piperazine citrate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE CITRATE remains US FDA's Preferred Term for this commodity. Piperazine citrate bears US NLM identifiers UMLS ID C1145666 and NCI Concept Code C47674. SMILES: C1CNCCN1.C1CNCCN1.C1CNCCN1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.O.

UNSPSC 51453005 Piperazine citrate is a Commodity code that maps nominally to a specific pharmaceutical ingredient, but recent state and local contract opportunities show little activity directly aligned with this code's stated scope. The code shows minimal recent procurement activity under its literal definition. Instead, the opportunities tagged to this code span broader pharmaceutical procurement—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products distributed through cooperative purchasing—none of which center on piperazine citrate as a primary deliverable or procurement focus. The mismatch between the code's narrow chemical definition and the actual scope of recent opportunities suggests either misclassification of opportunities in source systems or that piperazine citrate procurement does not generate regular competitive solicitations at the state and local level.

The recent opportunities posted under this code span diverse issuing bodies: Seminole County, Florida (county health procurement); the Texas Health and Human Services Commission (state-level RFI for pharmacy benefit strategy); the City of Tampa (municipal fire department supply bid); and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state cooperative vehicle administered by Minnesota Department of Administration). Geographic activity appears concentrated in Florida, Texas, and Minnesota based on recent postings, with the MMCAP cooperative vehicle serving additional states including Oregon. Representative recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, with 1,900 units of naloxone and 800 deactivation systems annually); the City of Tampa's ITB for medical and first aid supplies (estimated $700 million with SLBE set-aside, due March 13, 2026); and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, effective July 1, 2026). The code warrants close scrutiny for potential classification errors or scope drift in procurement systems before committing business development resources.